A phase III study of IVIG-SN (human normal immunoglobulin G for intravenous administration) for the treatment of primary immunodeficiency diseases (PID).

Trial Profile

A phase III study of IVIG-SN (human normal immunoglobulin G for intravenous administration) for the treatment of primary immunodeficiency diseases (PID).

Recruiting
Phase of Trial: Phase III

Latest Information Update: 25 Jan 2016

At a glance

  • Drugs Immune globulin (Primary)
  • Indications Immunodeficiency disorders
  • Focus Therapeutic Use
  • Most Recent Events

    • 25 Jan 2016 According to a Green Cross media release, Primary endpoint (Acute serious bacterial infection per patient-year) has been met.
    • 25 Jan 2016 According to a Green Cross media release, IVIG-SN demonstrated positive results in the treatment of primary immunodeficiency diseases (PID) in a phase III study.
    • 27 Nov 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top